Circulating microRNAs in cancer: Diagnostic and prognostic significance

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 283-288

  Zhou, Li ^a   Zhao, Yu Pei ^a   Liu, Wen Jing ^a   Dong, Jie ^a   Chen, Wei Yun ^a   Zhang, Tai Ping ^a   Chen, Ge ^a   Shu, Hong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

cancer; diagnosis; microRNAs; prognosis

Indexed keywords

MICRORNA; MICRORNA 106A; MICRORNA 10B; MICRORNA 1254; MICRORNA 126; MICRORNA 14 5P; MICRORNA 141; MICRORNA 145; MICRORNA 146B; MICRORNA 155; MICRORNA 16; MICRORNA 182; MICRORNA 195; MICRORNA 197; MICRORNA 199A; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 27A; MICRORNA 29C; MICRORNA 335; MICRORNA 34A; MICRORNA 425; MICRORNA 486 5P; MICRORNA 574 5P; MICRORNA 589; MICRORNA LET7A; MICRORNA LET7C; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; HUMAN; LUNG CANCER; NEOPLASM; OVARY CANCER; OVERALL SURVIVAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SOLID TUMOR;

ANIMALS; HUMANS; MICRORNAS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863116128     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.197     Document Type: Review

References (56)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000). (Pubitemid 30046295)
2. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10(4), 147-154 (2000). (Pubitemid 30171309)
3. Lebofsky R, Walter JC. New Myc-anisms for DNA replication and tumorigenesis? Cancer Cell 12(2), 102-103 (2007). (Pubitemid 47199128)
4. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 41(16), 2449-2461 (2005). (Pubitemid 41540622)
5. Musgrove EA. Cyclins: Roles in mitogenic signaling and oncogenic transformation. Growth Factors 24(1), 13-19 (2006). (Pubitemid 43108773)
6. Bourdon JC. p53 and its isoforms in cancer. Br. J. Cancer 97(3), 277-282 (2007).
7. Hock A, Vousden KH. Regulation of the p53 pathway by ubiquitin and related proteins. Int. J. Biochem. Cell Biol. 42(10), 1618-1621 (2010).
8. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993). (Pubitemid 24014542)
9. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J. Pathol. 223(2), 102-115 (2011).
10. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141(5), 672-675 (2008). (Pubitemid 351667616)
11. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
12. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. Expert Opin. Biol. Ther. 9, 703-711 (2009).
13. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2, 89 (2009).
14. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 251(3), 499-505 (2010).
15. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 119(3), 586-593 (2010).
16. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 57(1), 84-91 (2011).
17. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12(6), R90 (2010).
18. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS. One 5(10), e13735 (2010).
19. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol. 5(3), 281-291 (2011).
20. Chen X, Hu Z, Wang W et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for non-small cell lung cancer diagnosis. Int. J. Cancer doi:10.1002/ijc.26177 (2011) (Epub ahead of print).
21. Keller A, Leidinger P, Gislefoss R et al. Stable serum miRNA profiles as potential tool for noninvasive lung cancer diagnosis. RNA Biol. 8(3), 506-516 (2011).
22. Zheng D, Haddadin S, Wang Y et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4(6), 575-586 (2011).
23. Wei J, Gao W, Zhu CJ et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 30(6), 407-414 (2011).
24. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: Serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol. 6(3), 482-488 (2011).
25. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating microRNA expression profiles in early stage non-small cell lung cancer. Int. J. Cancer doi:10.1002/ijc.26153 (2011) (Epub ahead of print).
26. Shen J, Liu Z, Todd NW et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11(1), 374 (2011).
27. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28(10), 1721-1726 (2010).
28. Liu XG, Zhu WY, Huang YY et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. doi:10.1007/s12032-011-9923-y (2011) (Epub ahead of print).
29. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
30. Brase JC, Johannes M, Schlomm T et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128(3), 608-616 (2011).
31. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating microRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 9(1), 39-45 (2011).
32. Dong J, Zhao YP, Zhou L, Zhang TP, Chen G. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch. Med. Res. 42(1), 8-14 (2011).
33. Pan X, Wang ZX, Wang R. MicroRNA-21: A novel therapeutic target in human cancer. Cancer Biol. Ther. 10(12), 1224-1232 (2011).
34. Zhang HL, Yang LF, Zhu Y et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapyy. Prostate 71(3), 326-331 (2011).
35. Moltzahn F, Olshen AB, Baehner L et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 71(2), 550-560 (2011).
36. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5), 1265.e9-e16 (2011).
37. Yang CC, Hung PS, Wang PW et al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J. Oral Pathol. Med. 40(5), 397-404 (2011).
38. Zhang C, Wang C, Chen X et al. Expression profile of microRNAs in serum: A fingerprint for esophageal squamous cell carcinoma. Clin. Chem. 56(12), 1871-1879 (2010).
39. Liu R, Zhang C, Hu Z et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47(5), 784-791 (2011).
40. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4(7), e6229 (2009).
41. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127(1), 118-126 (2010).
42. Cheng H, Zhang L, Cogdell DE et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6(3), e17745 (2011).
43. Li A, Omura N, Hong SM et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 70(13), 5226-5237 (2010).
44. LaConti JJ, Shivapurkar N, Preet A et al. Tissue and serum microRNAs in the KrasG12D transgenic animal model and in patients with pancreatic cancer. PLoS One 6(6), e20687 (2011).
45. Xu J, Wu C, Che X et al. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 50(2), 136-142 (2011).
46. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem. Biophys. Res. Commun. 406(1), 70-73 (2011).
47. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol. 45(4), 355-360 (2011).
48. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112(1), 55-59 (2009).
49. Guo HQ, Huang GL, Guo CC, Pu XX, Lin TY. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis. Markers 29(5), 251-258 (2010).
50. Miyachi M, Tsuchiya K, Yoshida H et al. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 400(1), 89-93 (2010).
51. Murray MJ, Halsall DJ, Hook CE, Williams DM, Nicholson JC, Coleman N. Identification of microRNAs from the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am. J. Clin. Pathol. 135(1), 119-125 (2011).
52. Kanemaru H, Fukushima S, Yamashita J et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 61(3), 187-193 (2011).
53. Patnaik SK, Mallick R, Yendamuri S. Detection of microRNAs in dried serum blots. Anal. Biochem. 407(1), 147-149 (2010).
54. Weber JA, Baxter DH, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11), 1733-41 (2010).
55. Xie L, Chen X, Wang L et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 10(1), 591 (2010).
56. Shigehara K, Yokomuro S, Ishibashi O et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6(8), e23584 (2011).